JP Morgan Chase
STRO icon

JP Morgan Chase’s Sutro Biopharma STRO Stock Holding History

JP Morgan Chase’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.32M Buy
+159,627
New +$4.98M ﹤0.01% 3399
2026
Q1 		– Sell
-741
Closed -$8.57K – 7878
2025
Q4 		$8.57K Sell
741
-6,875
-90% -$65.2K ﹤0.01% 6707
2025
Q3 		$66.1K Sell
7,616
-9,732
-56% -$82.8K ﹤0.01% 6118
2025
Q2 		$124K Sell
17,348
-12,793
-42% -$105K ﹤0.01% 5509
2025
Q1 		$196K Buy
30,141
+23,736
+371% +$374K ﹤0.01% 5248
2024
Q4 		$118K Buy
6,405
+511
+9% +$15.6K ﹤0.01% 5692
2024
Q3 		$204K Buy
5,894
+70
+1% +$2.74K ﹤0.01% 5400
2024
Q2 		$171K Buy
5,824
+950
+19% +$37.6K ﹤0.01% 5239
2024
Q1 		$275K Sell
4,874
-1,740
-26% -$76.9K ﹤0.01% 5163
2023
Q4 		$284K Sell
6,614
-1,068
-14% -$33.9K ﹤0.01% 5139
2023
Q3 		$267K Buy
7,682
+211
+3% +$9.19K ﹤0.01% 4877
2023
Q2 		$347K Buy
7,471
+304
+4% +$15.1K ﹤0.01% 4719
2023
Q1 		$332K Sell
7,167
-11,611
-62% -$737K ﹤0.01% 4746
2022
Q4 		$1.52M Buy
18,778
+3,220
+21% +$224K ﹤0.01% 3768
2022
Q3 		$864K Sell
15,558
-85
-0.5% -$5.03K ﹤0.01% 4112
2022
Q2 		$815K Sell
15,643
-1,434
-8% -$80.1K ﹤0.01% 4245
2022
Q1 		$1.4M Buy
17,077
+11,461
+204% +$1.09M ﹤0.01% 4033
2021
Q4 		$836K Sell
5,616
-56
-1% -$10K ﹤0.01% 4513
2021
Q3 		$1.07M Sell
5,672
-643
-10% -$122K ﹤0.01% 4257
2021
Q2 		$1.17M Buy
6,315
+406
+7% +$79.5K ﹤0.01% 4185
2021
Q1 		$1.34M Sell
5,909
-751
-11% -$178K ﹤0.01% 4003
2020
Q4 		$1.45M Sell
6,660
-581
-8% -$96.2K ﹤0.01% 3713
2020
Q3 		$745K Sell
7,241
-1,006
-12% -$95K ﹤0.01% 3794
2020
Q2 		$640K Sell
8,247
-1,940
-19% -$186K ﹤0.01% 3743
2020
Q1 		$1.04M Sell
10,187
-155
-1% -$16.3K ﹤0.01% 3377
2019
Q4 		$1.14M Buy
10,342
+488
+5% +$50.3K ﹤0.01% 3758
2019
Q3 		$896K Buy
9,854
+350
+4% +$35.3K ﹤0.01% 3897
2019
Q2 		$1.08M Sell
9,504
-82
-0.9% -$9.04K ﹤0.01% 3818
2019
Q1 		$1.09M Sell
9,586
-359
-4% -$37.3K ﹤0.01% 3750
2018
Q4 		$898K Sell
9,945
-60
-0.6% -$7.24K ﹤0.01% 3813
2018
Q3 		$1.5M Buy
+10,005
New +$1.51M ﹤0.01% 3660

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

JP Morgan Chase's STRO Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Sutro Biopharma (STRO) in Q2 2026: 159,627 shares worth $5.32M. The stake represents ﹤0.01% of the portfolio and ranks #3399 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in STRO as recently as Q4 2025.

JP Morgan Chase first reported a position in STRO in Q3 2018 and has held it in 31 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • JP Morgan Chase held 159,627 shares of Sutro Biopharma worth $5.32M as of Q2 2026.
  • Sutro Biopharma was a new JP Morgan Chase position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3399 holding.
  • JP Morgan Chase first reported a position in Sutro Biopharma in Q3 2018 and has held it in 31 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.